Concepts (200)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 3 | 2021 | 59 | 1.930 |
Why?
|
| Antiviral Agents | 6 | 2020 | 211 | 1.580 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2018 | 10 | 1.130 |
Why?
|
| Constipation | 2 | 2018 | 32 | 1.100 |
Why?
|
| Hepatitis C, Chronic | 4 | 2020 | 86 | 1.050 |
Why?
|
| Drug Costs | 2 | 2020 | 87 | 0.850 |
Why?
|
| Meningitis, Pneumococcal | 1 | 2021 | 2 | 0.790 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2021 | 8 | 0.790 |
Why?
|
| Pneumococcal Vaccines | 1 | 2021 | 30 | 0.770 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2020 | 23 | 0.710 |
Why?
|
| Virus Activation | 1 | 2019 | 15 | 0.700 |
Why?
|
| Hepatitis B, Chronic | 1 | 2019 | 19 | 0.680 |
Why?
|
| Bacteremia | 1 | 2021 | 155 | 0.670 |
Why?
|
| Natriuretic Peptides | 1 | 2018 | 12 | 0.650 |
Why?
|
| Food Hypersensitivity | 1 | 2018 | 20 | 0.650 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2020 | 157 | 0.630 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 504 | 0.620 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 1026 | 0.510 |
Why?
|
| Mesalamine | 1 | 2012 | 6 | 0.430 |
Why?
|
| Depression | 1 | 2020 | 943 | 0.430 |
Why?
|
| Medication Adherence | 2 | 2022 | 335 | 0.420 |
Why?
|
| Colitis, Ulcerative | 1 | 2012 | 53 | 0.410 |
Why?
|
| Enema | 1 | 2012 | 23 | 0.400 |
Why?
|
| Cohort Studies | 5 | 2022 | 2358 | 0.400 |
Why?
|
| Hepatitis C | 3 | 2020 | 114 | 0.400 |
Why?
|
| Humans | 32 | 2022 | 68618 | 0.390 |
Why?
|
| Immunosuppressive Agents | 3 | 2021 | 514 | 0.380 |
Why?
|
| Peptides | 1 | 2014 | 455 | 0.380 |
Why?
|
| Hydrogen Peroxide | 1 | 2012 | 168 | 0.380 |
Why?
|
| Gout Suppressants | 1 | 2010 | 7 | 0.360 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 240 | 0.360 |
Why?
|
| Gout | 1 | 2010 | 9 | 0.360 |
Why?
|
| Hyperuricemia | 1 | 2010 | 13 | 0.360 |
Why?
|
| Colitis | 1 | 2012 | 156 | 0.360 |
Why?
|
| Thiazoles | 1 | 2010 | 95 | 0.350 |
Why?
|
| Drug Interactions | 4 | 2016 | 289 | 0.340 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 212 | 0.340 |
Why?
|
| Hypertriglyceridemia | 1 | 2009 | 21 | 0.340 |
Why?
|
| Disabled Persons | 2 | 2022 | 94 | 0.330 |
Why?
|
| Hypolipidemic Agents | 1 | 2009 | 82 | 0.320 |
Why?
|
| Education, Pharmacy | 1 | 2010 | 102 | 0.320 |
Why?
|
| Educational Measurement | 1 | 2010 | 254 | 0.310 |
Why?
|
| Hepacivirus | 2 | 2020 | 90 | 0.300 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2022 | 504 | 0.290 |
Why?
|
| Gastrointestinal Agents | 2 | 2018 | 51 | 0.290 |
Why?
|
| Pancreatitis | 1 | 2009 | 279 | 0.280 |
Why?
|
| Biosimilar Pharmaceuticals | 2 | 2019 | 25 | 0.280 |
Why?
|
| Retrospective Studies | 8 | 2022 | 7277 | 0.270 |
Why?
|
| United States | 7 | 2022 | 7367 | 0.230 |
Why?
|
| Colorectal Neoplasms | 2 | 2020 | 561 | 0.230 |
Why?
|
| Risk Assessment | 2 | 2021 | 2007 | 0.230 |
Why?
|
| Insulin | 2 | 2021 | 619 | 0.220 |
Why?
|
| Male | 10 | 2021 | 37321 | 0.220 |
Why?
|
| Stress, Psychological | 2 | 2020 | 824 | 0.210 |
Why?
|
| Middle Aged | 6 | 2022 | 21147 | 0.210 |
Why?
|
| Medicaid | 3 | 2022 | 302 | 0.210 |
Why?
|
| Analgesics, Opioid | 3 | 2022 | 498 | 0.200 |
Why?
|
| Vaccines, Conjugate | 1 | 2021 | 11 | 0.200 |
Why?
|
| Intellectual Disability | 1 | 2022 | 114 | 0.200 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2020 | 122 | 0.190 |
Why?
|
| Female | 10 | 2022 | 38074 | 0.190 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 649 | 0.190 |
Why?
|
| Autism Spectrum Disorder | 1 | 2022 | 111 | 0.190 |
Why?
|
| Pre-Eclampsia | 1 | 2022 | 202 | 0.180 |
Why?
|
| Drug Approval | 3 | 2016 | 50 | 0.180 |
Why?
|
| Chronic Pain | 1 | 2022 | 110 | 0.180 |
Why?
|
| Mercaptopurine | 1 | 2020 | 9 | 0.180 |
Why?
|
| Azathioprine | 1 | 2020 | 16 | 0.180 |
Why?
|
| Diet, Western | 1 | 2020 | 17 | 0.180 |
Why?
|
| Biological Therapy | 1 | 2020 | 8 | 0.180 |
Why?
|
| Education, Continuing | 1 | 2020 | 28 | 0.180 |
Why?
|
| Adult | 7 | 2021 | 21403 | 0.170 |
Why?
|
| Markov Chains | 1 | 2020 | 133 | 0.170 |
Why?
|
| Antirheumatic Agents | 1 | 2020 | 59 | 0.170 |
Why?
|
| Coinfection | 1 | 2019 | 30 | 0.170 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 1070 | 0.170 |
Why?
|
| Pharmacists | 2 | 2020 | 125 | 0.170 |
Why?
|
| Filgrastim | 1 | 2019 | 22 | 0.170 |
Why?
|
| Virus Replication | 1 | 2019 | 104 | 0.170 |
Why?
|
| Receptors, Guanylate Cyclase-Coupled | 1 | 2018 | 1 | 0.160 |
Why?
|
| Acute Disease | 2 | 2012 | 658 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 101 | 0.160 |
Why?
|
| Social Media | 1 | 2020 | 59 | 0.160 |
Why?
|
| Neutropenia | 1 | 2019 | 72 | 0.160 |
Why?
|
| Perception | 1 | 2020 | 189 | 0.160 |
Why?
|
| Drug Industry | 1 | 2019 | 54 | 0.160 |
Why?
|
| Prescriptions | 1 | 2018 | 28 | 0.160 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1851 | 0.160 |
Why?
|
| Cost Savings | 1 | 2019 | 110 | 0.160 |
Why?
|
| Bacteria | 1 | 2020 | 193 | 0.160 |
Why?
|
| Clinical Trials as Topic | 2 | 2014 | 848 | 0.160 |
Why?
|
| Sepsis | 1 | 2021 | 233 | 0.150 |
Why?
|
| Health Care Costs | 1 | 2020 | 346 | 0.150 |
Why?
|
| Comorbidity | 1 | 2021 | 1426 | 0.140 |
Why?
|
| Health Personnel | 1 | 2020 | 286 | 0.140 |
Why?
|
| Levalbuterol | 1 | 2016 | 1 | 0.140 |
Why?
|
| Albuterol | 1 | 2016 | 26 | 0.140 |
Why?
|
| Obesity | 2 | 2022 | 1076 | 0.140 |
Why?
|
| Bronchodilator Agents | 1 | 2016 | 43 | 0.140 |
Why?
|
| Mass Screening | 2 | 2019 | 843 | 0.130 |
Why?
|
| Health Expenditures | 1 | 2018 | 170 | 0.130 |
Why?
|
| Whipple Disease | 1 | 2015 | 4 | 0.130 |
Why?
|
| Remission Induction | 1 | 2016 | 111 | 0.130 |
Why?
|
| Ceftriaxone | 1 | 2015 | 32 | 0.130 |
Why?
|
| Professional Role | 1 | 2016 | 80 | 0.130 |
Why?
|
| Minocycline | 1 | 2015 | 61 | 0.130 |
Why?
|
| Risk Factors | 3 | 2020 | 5731 | 0.130 |
Why?
|
| Bariatric Surgery | 1 | 2016 | 90 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2016 | 151 | 0.120 |
Why?
|
| Pharmaceutical Services | 1 | 2014 | 47 | 0.120 |
Why?
|
| Glucocorticoids | 1 | 2016 | 222 | 0.120 |
Why?
|
| Obesity, Morbid | 1 | 2016 | 172 | 0.120 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 4848 | 0.120 |
Why?
|
| Age Factors | 1 | 2018 | 1864 | 0.110 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2014 | 77 | 0.110 |
Why?
|
| Gastrointestinal Diseases | 1 | 2014 | 107 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 438 | 0.110 |
Why?
|
| Infant, Newborn | 1 | 2018 | 2455 | 0.110 |
Why?
|
| Asthma | 1 | 2016 | 345 | 0.100 |
Why?
|
| Delayed-Action Preparations | 1 | 2012 | 120 | 0.100 |
Why?
|
| Veterans | 1 | 2020 | 904 | 0.100 |
Why?
|
| Infant | 1 | 2018 | 2891 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2018 | 7029 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 772 | 0.090 |
Why?
|
| Febuxostat | 1 | 2010 | 1 | 0.090 |
Why?
|
| Xanthine Oxidase | 1 | 2010 | 15 | 0.090 |
Why?
|
| Liver | 1 | 2016 | 1118 | 0.090 |
Why?
|
| Time Factors | 1 | 2018 | 4655 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 2279 | 0.090 |
Why?
|
| Professional Competence | 1 | 2010 | 100 | 0.080 |
Why?
|
| Gemfibrozil | 1 | 2009 | 4 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2014 | 1330 | 0.080 |
Why?
|
| Enoxaparin | 1 | 2009 | 51 | 0.080 |
Why?
|
| Age of Onset | 2 | 2020 | 188 | 0.080 |
Why?
|
| South Carolina | 3 | 2022 | 2752 | 0.080 |
Why?
|
| Neoplasms | 2 | 2019 | 1667 | 0.070 |
Why?
|
| United States Food and Drug Administration | 2 | 2019 | 131 | 0.070 |
Why?
|
| Aged | 2 | 2020 | 14862 | 0.070 |
Why?
|
| Pregnancy | 2 | 2022 | 2334 | 0.070 |
Why?
|
| Recurrence | 1 | 2009 | 948 | 0.070 |
Why?
|
| Animals | 2 | 2014 | 20881 | 0.070 |
Why?
|
| Models, Biological | 1 | 2010 | 981 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 2077 | 0.060 |
Why?
|
| Parturition | 1 | 2022 | 15 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2022 | 50 | 0.050 |
Why?
|
| Bias | 1 | 2022 | 148 | 0.050 |
Why?
|
| Overweight | 1 | 2022 | 186 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2022 | 234 | 0.050 |
Why?
|
| Sodium Glutamate | 1 | 2020 | 3 | 0.040 |
Why?
|
| High Fructose Corn Syrup | 1 | 2020 | 3 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2022 | 714 | 0.040 |
Why?
|
| Red Meat | 1 | 2020 | 10 | 0.040 |
Why?
|
| Flavoring Agents | 1 | 2020 | 24 | 0.040 |
Why?
|
| Wisconsin | 1 | 2020 | 31 | 0.040 |
Why?
|
| Maryland | 1 | 2020 | 77 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 792 | 0.040 |
Why?
|
| Food Handling | 1 | 2020 | 34 | 0.040 |
Why?
|
| Coloring Agents | 1 | 2020 | 66 | 0.040 |
Why?
|
| Georgia | 1 | 2020 | 161 | 0.040 |
Why?
|
| Physician Assistants | 1 | 2020 | 47 | 0.040 |
Why?
|
| Critical Illness | 1 | 2021 | 191 | 0.040 |
Why?
|
| Hematologic Agents | 1 | 2019 | 11 | 0.040 |
Why?
|
| Japan | 1 | 2019 | 68 | 0.040 |
Why?
|
| Nurse Practitioners | 1 | 2020 | 90 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 384 | 0.040 |
Why?
|
| Titanium | 1 | 2020 | 118 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 196 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2020 | 113 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 344 | 0.040 |
Why?
|
| Immune System | 1 | 2018 | 63 | 0.040 |
Why?
|
| Canada | 1 | 2019 | 267 | 0.040 |
Why?
|
| Child | 2 | 2021 | 6405 | 0.040 |
Why?
|
| Gastrointestinal Tract | 1 | 2018 | 63 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 352 | 0.040 |
Why?
|
| Length of Stay | 1 | 2021 | 780 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2020 | 332 | 0.040 |
Why?
|
| Mothers | 1 | 2018 | 172 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 163 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 581 | 0.040 |
Why?
|
| Propensity Score | 1 | 2016 | 117 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2018 | 737 | 0.030 |
Why?
|
| Diet | 1 | 2020 | 514 | 0.030 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2016 | 4 | 0.030 |
Why?
|
| Long-Term Care | 1 | 2016 | 53 | 0.030 |
Why?
|
| Sustained Virologic Response | 1 | 2016 | 11 | 0.030 |
Why?
|
| Physicians | 1 | 2020 | 324 | 0.030 |
Why?
|
| Societies, Pharmaceutical | 1 | 2016 | 22 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 694 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2018 | 384 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2016 | 304 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 786 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1603 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2020 | 596 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2016 | 301 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 2800 | 0.020 |
Why?
|
| Hospitalization | 1 | 2016 | 978 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 711 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 3187 | 0.020 |
Why?
|
| Young Adult | 1 | 2020 | 5717 | 0.020 |
Why?
|
| Adolescent | 1 | 2016 | 8912 | 0.010 |
Why?
|